方法：将2011-01/2014-02期间我院收治的新生血管性青光眼患者纳入研究，根据治疗方法不同分为接受中西医药物配合小梁切除术治疗的观察组和接受西医药物配合小梁切除术治疗的对照组，比较两组患者的视力水平、眼压、视网膜神经纤维层厚度。

结果：视力水平：治疗后1wk； 6，12mo，观察组的患眼视力水平均明显高于对照组(0.41±0.07 vs 0.27±0.04，0.52±0.08 vs 0.38±0.06， 0.72±0.14 vs 0.54±0.08)； 眼压：治疗后1wk； 6，12mo，观察组眼压明显低于对照组(15.11±3.22 vs 22.32±5.34， 18.64±5.08 vs 26.67±6.22， 17.18±3.76 vs 22.42±4.32)mmHg； 视网膜神经纤维层厚度：治疗后12mo，观察组上方视野、下方视野、颞侧视野、鼻侧视野等神经纤维层厚度等神经纤维层厚度均明显高于对照组(90.41±10.52 vs 78.64±8.24， 88.38±12.12 vs 72.37±8.82， 73.21±8.46 vs 60.25±7.23， 75.35±8.13 vs 62.63±7.29)μm。

结论：当归芍药散配合小梁切除术联合bevacizumab治疗新生血管性青光眼有助于促进视力水平的恢复、控制眼压、改善视网膜神经纤维层厚度。

METHODS:Neovascular glaucoma patients were enrolled from January 2011 to February 2014 in our hospital, according to the different methods of treatment were divided into observation group given traditional Chinese medicine and Western medicine combined with trabeculectomy, and control group received Western medicine combined with trabeculectomy. Visual acuity, intraocular pressure, retinal thickness were compared.

RESULTS: Visual acuity level: 1wk; 6, 12mo after treatment, visual acuity in observation group were significantly higher than that in control group(0.41±0.07 vs 0.27±0.04, 0.52±0.08 vs 0.38±0.06, 0.72±0.14 vs 0.54±0.08); Intraocular pressure: 1wk; 6, 12mo after treatment, intraocular pressure in observation group were significantly lower than that in control group(15.11±3.22 vs 22.32±5.34, 18.64±5.08 vs 26.67±6.22, 17.18±3.76 vs 22.42±4.32)mmHg; Retinal nerve fiber layer thickness: 12mo after treatment, nerve fiber layer thickness in observation group was significantly higher than that in control group(90.41±10.52 vs 78.64±8.24, 88.38±12.12 vs 72.37±8.82, 73.21±8.46 vs 60.25±7.23, 75.35±8.13 vs 62.63±7.29)μm.

CONCLUSION:Danggui Shaoyao Powder combined with trabeculectomy and bevacizumab on neovascular glaucoma can promote visual acuity recovery, control intraocular pressure, and improve the retinal nerve fiber layer thickness.